WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design
Nearly 9 in 10 people prefer personalized breast cancer screening based on individual risk, showing strong public support for moving beyond one-size-fits-all approaches.
The WISDOM Study reports cohort characteristics and design of a large, nationwide pragmatic RCT (n=46,403) comparing risk-based versus annual breast cancer screening using the BCSC model and genetic risk assessment. The preference-tolerant design revealed that 89% of self-selecting participants chose risk-based screening, strongly validating public acceptability and setting the stage for definitive efficacy outcomes from this landmark trial.
What the study was
- Study design
- Pragmatic randomized controlled trial (cohort design paper)
- Population
- Women aged 40-74 enrolled in breast cancer screening programs across US (diverse cohort; 77% non-Hispanic White, 9% Hispanic, 6% Black, 5% Asian)
- Sample size
- 46403
- Category
- Early Detection
- Maturity
- Validated
- Journal
- NPJ Breast Cancer
Why it surfaced
This is the design/cohort paper for the WISDOM pragmatic RCT — one of the most important ongoing breast cancer early detection trials globally. Score of 7 (below 8 threshold) is elevated to HIGH by EARLY_CANCER_DETECTION flag per pipeline rules. The 89% self-selection rate for risk-based screening is a notable finding for real-world implementation. Note: this is NOT the efficacy outcomes paper; scored conservatively given no primary endpoint results reported yet.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.